2023
Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer
Han J, Zakeri K, Raab G, Hesse J, Shamseddine A, Chen L, Yu Y, Kang J, McBride S, Riaz N, Tsai C, Gelblum D, Sherman E, Wong R, Michel L, Lee N. Concurrent carboplatin and paclitaxel definitive radiation therapy for locally advanced head and neck cancer. Head & Neck 2023, 45: 2207-2216. PMID: 37439286, PMCID: PMC10981461, DOI: 10.1002/hed.27456.Peer-Reviewed Original ResearchConceptsLocoregional recurrenceDistant metastasisOverall survivalHNSCC patientsConcurrent carboplatinDefinitive chemoradiationConsecutive HNSCC patientsDefinitive radiation therapyMedian radiation doseKaplan-Meier methodCumulative incidence functionFree survivalAdvanced headMedian ageMedian dosesNeck cancerAUC 1Radiation therapyCarboplatinPatientsChemoradiationPaclitaxelRadiation doseExcellent optionIncidence function
2022
Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy
Tsai CJ, McBride SM, Riaz N, Kang JJ, Spielsinger DJ, Waldenberg T, Gelblum D, Yu Y, Chen LC, Zakeri K, Wong RJ, Dunn L, Pfister DG, Sherman EJ, Lee NY. Evaluation of Substantial Reduction in Elective Radiotherapy Dose and Field in Patients With Human Papillomavirus–Associated Oropharyngeal Carcinoma Treated With Definitive Chemoradiotherapy. JAMA Oncology 2022, 8: 364-372. PMID: 35050342, PMCID: PMC8778604, DOI: 10.1001/jamaoncol.2021.6416.Peer-Reviewed Original ResearchConceptsDistant metastasis-free survivalProgression-free survivalMetastasis-free survivalOropharyngeal carcinomaConcurrent chemoradiotherapyDe-escalation strategiesRadiotherapy doseTotal doseSubclinical regionsLocoregional controlGross diseaseCohort studyOverall survivalClinical outcomesHuman Papillomavirus–Associated Oropharyngeal CarcinomaHigh-dose cisplatin therapyHPV-positive oropharyngeal carcinomaTarget volumeBilateral level IBGy of radiotherapyPrimary concurrent chemoradiotherapyRetrospective cohort studyFavorable clinical outcomeAmerican Joint CommitteeLong-term follow
2021
TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence
Yu Y, Fan D, Song X, Zakeri K, Chen L, Kang J, McBride S, Tsai CJ, Dunn L, Sherman E, Katabi N, Dogan S, Cracchiolo J, Cohen M, Boyle JO, Lee M, Valero C, Wang J, Wong R, Morris L, Riaz N, Lee N. TERT Promoter Mutations Are Enriched in Oral Cavity Cancers and Associated With Locoregional Recurrence. JCO Precision Oncology 2021, 5: 1259-1269. PMID: 34381934, PMCID: PMC8345918, DOI: 10.1200/po.20.00515.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaLocoregional failurePatterns of failureCumulative incidenceCell carcinomaPromoter mutationsHPV-positive oropharyngeal squamous cell carcinomaMemorial Sloan-Kettering Cancer CenterRisk of LRFOropharyngeal squamous cell carcinomaNeck squamous cell carcinomaHPV-negative HNSCCsReverse transcriptase (TERT) promoter mutationsOral cavity cancerNext-generation sequencingTERT promoter mutationsDisease subsiteLocoregional recurrenceOverall cohortOverall survivalProspective cohortCancer CenterHuman papillomavirusLaryngopharyngeal cancerUnique pathogenesisProton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot
Lee A, Kang J, Bernstein H, Marqueen K, Neal B, Kelly C, Dickson M, Tsai C, Tap W, Singer S, Alektiar K, Lee N. Proton radiotherapy for recurrent or metastatic sarcoma with palliative quad shot. Cancer Medicine 2021, 10: 4221-4227. PMID: 34085781, PMCID: PMC8267151, DOI: 10.1002/cam4.3646.Peer-Reviewed Original ResearchConceptsLocal progression-free survivalMetastatic sarcomaSystemic therapyQUAD ShotOverall survivalUnivariate analysisPalliative responseMedian local progression-free survivalGrade 3 acute toxicityFurther systemic therapyProgression-free survivalConcurrent systemic therapyProton therapyCommon histologyMedian followProton RTTreatment optionsRadiation therapyPatientsLocal controlSarcomaTherapyRegimenProton radiotherapyAcute toxicityAny day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center
Kang JJ, Tchekmedyian V, Mohammed N, Rybkin A, Kitpanit S, Fan M, Wang H, Lobaugh SM, Zhang Z, Lee A, Chen L, Yu Y, Zakeri K, Gelblum DY, Riaz N, McBride SM, Tsai CJ, Cohen MA, Cracchiolo JR, Morris LG, Singh B, Patel S, Ganly I, Boyle JO, Wong RJ, Eng J, Zhi WI, Ng K, Ho AL, Dunn LA, Michel L, Fetten JV, Pfister DG, Lee NY, Sherman EJ. Any day, split halfway: Flexibility in scheduling high‐dose cisplatin—A large retrospective review from a high‐volume cancer center. International Journal Of Cancer 2021, 149: 139-148. PMID: 33586179, PMCID: PMC9380235, DOI: 10.1002/ijc.33518.Peer-Reviewed Original ResearchConceptsTotal cumulative doseHigh-dose cisplatinLocoregional failureOverall survivalOropharyngeal cancerDistant metastasisRegional failureHigh-volume cancer centerLocal failureAlternate dosing schedulesHuman papillomavirus (HPV) statusKarnofsky performance statusCooperative group trialsAdvanced oropharyngeal cancerLarge retrospective reviewStandard of careMultivariable regression modelsDefinitive chemoradiationInduction chemotherapyPerformance statusDosing schedulesTherapy startAdministration dayRetrospective reviewRenal toxicity
2020
Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers
Fan D, Kang JJ, Fan M, Wang H, Lee A, Yu Y, Chen L, Tsai C, McBride SM, Riaz N, Gelblum DY, Neal BP, Fetten J, Dunn LA, Michel LS, Boyle JO, Cohen MA, Roman BR, Ganly I, Singh B, Wong RJ, Sherman EJ, Lee NY. Last-line local treatment with the Quad Shot regimen for previously irradiated head and neck cancers. Oral Oncology 2020, 104: 104641. PMID: 32182548, PMCID: PMC8480112, DOI: 10.1016/j.oraloncology.2020.104641.Peer-Reviewed Original ResearchConceptsLocoregional progression-free survivalQuad Shot regimenOverall survivalPalliative responseRadiation therapyNeck cancerMedian locoregional progression-free survivalGrade 3 toxicity ratesOverall palliative response rateMedian overall survivalPalliative response ratePrior radiation therapyProgression-free survivalRadiation-related toxicityFree survivalPalliative therapyMedian ageLocal therapyPalliative optionSurvival improvementProton radiation therapyToxicity ratesTumor reductionIrradiated headLocal treatmentOutcomes and toxicities of definitive radiotherapy and reirradiation using 3‐dimensional conformal or intensity‐modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies
Fan M, Kang JJ, Lee A, Fan D, Wang H, Kitpanit S, Fox P, Sine K, Mah D, McBride SM, Tsai CJ, Riaz N, Dunn LA, Sherman EJ, Michel L, Singh B, Ganly I, Wong RJ, Boyle JO, Cohen MA, Lee NY. Outcomes and toxicities of definitive radiotherapy and reirradiation using 3‐dimensional conformal or intensity‐modulated (pencil beam) proton therapy for patients with nasal cavity and paranasal sinus malignancies. Cancer 2020, 126: 1905-1916. PMID: 32097507, PMCID: PMC7304541, DOI: 10.1002/cncr.32776.Peer-Reviewed Original ResearchConceptsGrade 3 toxicityRadiation-naive patientsIntensity-modulated proton therapyLate grade 3 toxicityParanasal sinus cancerLocal controlNasal cavitySinus cancerAcute grade 3 toxicityGray relative biological effectivenessProton therapyMore grade 1Paranasal sinus malignanciesRemarkable local controlDisease-free survivalInferior local controlOverall survival rateDefinitive radiotherapyConsecutive patientsSinus malignanciesMedian dosesHigher complicationsDistant controlTherapeutic ratioPatients
2019
Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer
Beckham TH, Barney C, Healy E, Wolfe AR, Branstetter A, Yaney A, Riaz N, McBride SM, Tsai CJ, Kang J, Yu Y, Chen L, Sherman E, Dunn L, Pfister DG, Tan J, Rupert R, Bonomi M, Zhang Z, Lobaugh SM, Grecula JC, Mitchell DL, Wobb JL, Miller ED, Blakaj DM, Diavolitsis VM, Lee N, Bhatt AD. Platinum‐based regimens versus cetuximab in definitive chemoradiation for human papillomavirus‐unrelated head and neck cancer. International Journal Of Cancer 2019, 147: 107-115. PMID: 31609479, DOI: 10.1002/ijc.32736.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCetuximabChemoradiotherapyCisplatinFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedNeoplasm StagingPapillomaviridaePapillomavirus InfectionsRandomized Controlled Trials as TopicSquamous Cell Carcinoma of Head and NeckSurvival RateConceptsLocoregional failureOverall survivalDistant metastasisReduced hazardMultivariable analysisKaplan-MeierHuman papillomavirus-unrelated headNeck squamous cell carcinomaPlatinum-based regimensSquamous cell carcinomaSuperior locoregional controlCumulative incidence functionDefinitive chemoradiationDefinitive radiotherapyLocoregional controlAdvanced headClinical characteristicsCumulative incidenceConcurrent cetuximabPropensity matchingYear OSCell carcinomaHuman papillomavirusNeck cancerProportional hazardsOutcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer
Fan D, Ma J, Bell AC, Groen AH, Olsen KS, Lok BH, Leeman JE, Anderson E, Riaz N, McBride S, Ganly I, Shaha AR, Sherman EJ, Tsai CJ, Kang JJ, Lee NY. Outcomes of multimodal therapy in a large series of patients with anaplastic thyroid cancer. Cancer 2019, 126: 444-452. PMID: 31593317, PMCID: PMC7302673, DOI: 10.1002/cncr.32548.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsChemoradiotherapy, AdjuvantDose-Response Relationship, RadiationDoxorubicinFemaleFollow-Up StudiesHumansIndazolesMaleMiddle AgedPaclitaxelProgression-Free SurvivalPyrimidinesRadiotherapy DosageRadiotherapy, Intensity-ModulatedRetrospective StudiesSulfonamidesThyroid Carcinoma, AnaplasticThyroid GlandThyroid NeoplasmsThyroidectomyTumor BurdenConceptsLocoregional progression-free survivalRole of radiotherapyAnaplastic thyroid cancerTreatment of patientsOverall survivalAdverse eventsMetastatic diseaseTrimodal therapyThyroid cancerAcute grade 3 adverse eventsAdvanced anaplastic thyroid cancerGrade 3 adverse eventsPostoperative RTDistant metastasis-free survivalTrimodal treatment approachAcceptable toxicity profileProgression-free survivalLate adverse eventsLocal tumor controlMetastasis-free survivalLong-term outcomesLPFS ratesOS benefitConcurrent chemoradiationSystemic agentsTiming of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach
Xiao R, Joshi RR, Husain Q, Cracchiolo JR, Lee N, Tsai J, Yu Y, Chen L, Kang JJ, McBride S, Riaz N, Roman BR, Ganly I, Tabar V, Gray ST, Cohen MA. Timing of surgery and adjuvant radiation therapy for sinonasal malignancies: Effect of surgical approach. Head & Neck 2019, 41: 3551-3563. PMID: 31294897, PMCID: PMC6742559, DOI: 10.1002/hed.25873.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedCarcinoma, Squamous CellCombined Modality TherapyDatabases, FactualDisease-Free SurvivalEndoscopyFemaleHumansKaplan-Meier EstimateLinear ModelsMaleMiddle AgedOtorhinolaryngologic Surgical ProceduresParanasal Sinus NeoplasmsPropensity ScoreRadiotherapy, AdjuvantRetrospective StudiesRisk AssessmentSurvival AnalysisTime FactorsConceptsSquamous cell carcinomaRadiation therapyEndoscopic surgeryPropensity score-matched analysisAdjuvant radiation therapyNational Cancer DatabasePostoperative radiation therapyKaplan-Meier methodTiming of surgeryDay of surgeryShorter postoperative timeMultivariable linear regressionOverall survivalPostoperative timeSinonasal malignanciesCell carcinomaSurgical approachNeck cancerCancer DatabaseParanasal sinusesSurvival advantageNasal cavitySurgeryPatientsExtended OS
2018
First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology
Kang JJ, Reiter RE, Steinberg ML, King CR. First Postprostatectomy Ultrasensitive Prostate-specific Antigen Predicts Survival in Patients with High-risk Prostate Cancer Pathology. European Urology Oncology 2018, 1: 378-385. PMID: 31158076, DOI: 10.1016/j.euo.2018.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedFollow-Up StudiesHumansMaleMargins of ExcisionMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingNeoplasm, ResidualPostoperative PeriodPrognosisProstatectomyProstate-Specific AntigenProstatic NeoplasmsRadiotherapy, AdjuvantRetrospective StudiesRisk FactorsSalvage TherapySurvival AnalysisConceptsBone metastasis-free survivalProstate cancer-specific survivalUltrasensitive prostate specific antigenOverall survivalBiochemical relapseProstate-specific antigenRadical prostatectomyMultivariate analysisProstate-specific antigen levelImmediate adjuvant therapyOccult prostate cancerOccult systemic diseaseCancer-specific survivalEarly salvage radiotherapyHigh-risk diseaseKaplan-Meier methodTraditional risk factorsMetastasis-free survivalPrediction of outcomeProstate cancer pathologyAdjuvant therapySalvage radiotherapyHormone therapyIndependent predictorsStudy endpointWhole Versus Partial Bladder Radiation
Kang J, Steinberg M, Kupelian P, Alexander S, King C. Whole Versus Partial Bladder Radiation. American Journal Of Clinical Oncology 2018, 41: 107-114. PMID: 26535994, DOI: 10.1097/coc.0000000000000237.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCarcinoma, Transitional CellCohort StudiesDisease-Free SurvivalFemaleGeriatric AssessmentHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm InvasivenessNeoplasm StagingOrgan Sparing TreatmentsPrognosisRadiation Dose HypofractionationRadiation InjuriesRadiotherapy, Image-GuidedRadiotherapy, Intensity-ModulatedRetrospective StudiesRisk AssessmentSurvival AnalysisTreatment OutcomeUnited StatesUrinary Bladder NeoplasmsConceptsOverall survivalLymph nodesWhole bladderLocal controlMuscle-invasive bladder cancerMuscle-invasive recurrenceMulti-institutional cohortSimultaneous integrated boostIntensity-modulated radiation therapyDefinitive chemoradiationPrimary endpointSecondary endpointsBladder treatmentLocal recurrenceUrothelial cancerMean ageBladder cancerIntegrated boostInstitutional experienceRetrospective analysisBladder wallBoost volumeRadiation therapySimilar survivalTherapeutic ratioWrong to be Right
Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. Wrong to be Right. American Journal Of Clinical Oncology 2018, 41: 1-5. PMID: 26237192, PMCID: PMC6946377, DOI: 10.1097/coc.0000000000000216.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnalysis of VarianceCohort StudiesDatabases, FactualDisease-Free SurvivalFollow-Up StudiesHumansKaplan-Meier EstimateMaleMargins of ExcisionMiddle AgedMultivariate AnalysisNeoplasm GradingNeoplasm Recurrence, LocalProportional Hazards ModelsProstate-Specific AntigenProstatectomyProstatic NeoplasmsRetrospective StudiesRisk AssessmentSalvage TherapySurvival AnalysisTreatment OutcomeConceptsSalvage radiation therapyRadical prostatectomyT stageCox multivariate analysisIntrinsic risk factorsIatrogenic failuresPostoperative PSASRT PSASalvage radiationBiochemical progressionIndependent predictorsLocal recurrencePreoperative PSARelapse rateBiochemical relapseKaplan-MeierBiochemical recurrenceSurgical approachRP patientsRisk factorsSurgical techniqueGleason gradeRadiation therapySurgical pathologyConsecutive rises